Dr. Reddy's Laboratories (RDY) Competitors $13.95 -0.27 (-1.90%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$13.94 -0.01 (-0.11%) As of 08/1/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDY vs. TAK, ARGX, ONC, BNTX, SMMT, INSM, TEVA, GMAB, MRNA, and QGENShould you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. Dr. Reddy's Laboratories vs. Its Competitors Takeda Pharmaceutical argenex BeOne Medicines BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna QIAGEN Takeda Pharmaceutical (NYSE:TAK) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation. Which has more risk and volatility, TAK or RDY? Takeda Pharmaceutical has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Does the media favor TAK or RDY? In the previous week, Takeda Pharmaceutical had 9 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 12 mentions for Takeda Pharmaceutical and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.61 beat Takeda Pharmaceutical's score of 0.49 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of TAK or RDY? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend TAK or RDY? Dr. Reddy's Laboratories has a consensus price target of $16.95, indicating a potential upside of 21.51%. Given Dr. Reddy's Laboratories' higher probable upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is TAK or RDY a better dividend stock? Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.9%. Dr. Reddy's Laboratories pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Takeda Pharmaceutical pays out 183.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Reddy's Laboratories pays out 10.6% of its earnings in the form of a dividend. Which has better earnings and valuation, TAK or RDY? Takeda Pharmaceutical has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$30.09B1.50$712.33M$0.3047.23Dr. Reddy's Laboratories$3.81B3.06$663M$0.6621.14 Is TAK or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Takeda Pharmaceutical's net margin of 3.20%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical3.20% 10.50% 5.10% Dr. Reddy's Laboratories 16.99%17.25%11.63% SummaryDr. Reddy's Laboratories beats Takeda Pharmaceutical on 12 of the 18 factors compared between the two stocks. Get Dr. Reddy's Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDY vs. The Competition Export to ExcelMetricDr. Reddy's LaboratoriesMED IndustryMedical SectorNYSE ExchangeMarket Cap$11.87B$3.75B$5.47B$20.69BDividend Yield0.51%1.17%4.73%3.67%P/E Ratio21.149.2028.6729.07Price / Sales3.0611.89422.5466.49Price / Cash13.776.3535.4522.84Price / Book2.822.658.274.43Net Income$663M-$109.62M$3.24B$994.22M7 Day Performance-4.88%-1.94%-3.64%-3.35%1 Month Performance-6.19%8.51%4.39%-2.06%1 Year Performance-16.21%24.02%25.97%10.15% Dr. Reddy's Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDYDr. Reddy's Laboratories1.9595 of 5 stars$13.95-1.9%$16.95+21.5%-15.5%$11.87B$3.81B21.1427,811TAKTakeda Pharmaceutical2.4038 of 5 stars$14.31-1.2%N/A+2.3%$46.07B$4.58T65.0547,455Gap UpARGXargenex2.8337 of 5 stars$595.19+0.5%$728.06+22.3%+30.5%$36.23B$2.25B36.721,599Trending NewsEarnings ReportAnalyst ForecastONCBeOne Medicines0.7258 of 5 stars$294.51+1.0%$327.56+11.2%N/A$31.95B$3.81B0.0011,000Upcoming EarningsInsider TradeGap UpBNTXBioNTech2.7453 of 5 stars$112.79-2.2%$136.58+21.1%+33.0%$27.72B$2.98B-33.176,772Upcoming EarningsSMMTSummit Therapeutics3.0125 of 5 stars$27.45-4.3%$34.67+26.3%+153.9%$21.29B$700K-80.73110Upcoming EarningsINSMInsmed3.768 of 5 stars$101.75-2.1%$109.20+7.3%+44.3%$19.72B$363.71M-17.101,271Upcoming EarningsTEVATeva Pharmaceutical Industries3.979 of 5 stars$16.53-0.1%$24.71+49.5%-12.3%$18.97B$16.54B-14.3736,830News CoveragePositive NewsEarnings ReportGap UpGMABGenmab A/S3.6745 of 5 stars$23.09-1.3%$37.80+63.7%-23.2%$15.01B$3.12B13.122,682News CoveragePositive NewsShort Interest ↑MRNAModerna4.4688 of 5 stars$33.91-0.7%$46.11+36.0%-70.7%$13.21B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownQGENQIAGEN3.3039 of 5 stars$51.00-1.5%$49.40-3.1%+12.1%$11.51B$1.98B127.875,765Upcoming Earnings Related Companies and Tools Related Companies Takeda Pharmaceutical Alternatives argenex Alternatives BeOne Medicines Alternatives BioNTech Alternatives Summit Therapeutics Alternatives Insmed Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Moderna Alternatives QIAGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RDY) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDY Stock Alerts